GlassScriptPhysician profile
Shannon Swift Cooper
NPI 1013141621
$573.12
in general payments reported to CMS, 2019-2025
14 companies · $109 in 2025
The $109 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.64 · 2020: $24.60 · 2021: $30.86 · 2022: $229 · 2023: $7.25 · 2024: $125 · 2025: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $241.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $129.64 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $116.82 | 2024-2025 | Rexulti |
| Novo Nordisk INC | $79.53 | 2019-2024 | Rybelsus |
| Glaxosmithkline, LLC. | $60.76 | 2022 | |
| Mylan Specialty L.P. | $46.03 | 2022-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $22.10 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.39 | 2022 | |
| Abbvie INC. | $17.66 | 2025 | |
| Xeris Pharmaceuticals, INC. | $17.08 | 2024 | Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $16.39 | 2021 | |
| Amgen INC. | $14.47 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.31 | 2024 | Xifaxan |
| Lilly USA, LLC | $12.69 | 2020 | |
| Organon LLC | $7.25 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.